Pioneering the mission of personalized patient care, Kokilaben Hospital leads in terms of early detection as to provide best treatment to cancer patients. The integration of genomics into the health care system has transformed the overall enterprise of life sciences with successful implementation of Precision Oncology. Kokilaben Hospital aims to provide a supportive journey to all cancer patients by providing a treatment strategy that is tailored to their unique genetic profile and build a personalized therapy customized for every patient. This provides an insight into choosing the effective treatment options like chemotherapy, targeted therapy or Immunotherapies, based on individual patient genetic makeup which crucially helps in the decision of treatment choice.
๐ฅ๐ฒ๐น๐ฒ๐๐ฎ๐ป๐ฐ๐ฒ ๐ผ๐ณ ๐ง๐ต๐ฒ ๐ ๐ผ๐น๐ฒ๐ฐ๐๐น๐ฎ๐ฟ ๐ง๐๐บ๐ผ๐ฟ ๐๐ผ๐ฎ๐ฟ๐ฑ
Kokilaben Hospital has dedicated in-house Molecular pathology and cancer genomics laboratory with inbuilt technologies and facilities like Next generation sequencing. The Molecular Tumor Board convenes experts in Surgical oncology, Medical oncology, Molecular Pathology and oncology, Radiation Oncology, Hematology, Histopathology, and clinical trials to discuss the best options for individual patients, based on the genomic alterations present in their cancer. In some cases, germline alterations detected in the patients normal DNA are also evaluated with the assistance of genetic counselors. These meetings are organized to help address diagnostic, prognostic and therapeutic questions and best possible clinical care decisions for their patients.
๐ช๐ต๐ ๐ถ๐ ๐ด๐ฒ๐ป๐ฒ๐๐ถ๐ฐ ๐๐ฒ๐๐๐ถ๐ป๐ด ๐ถ๐บ๐ฝ๐ผ๐ฟ๐๐ฎ๐ป๐?
Genetic testing for cancer may help in estimation of an individualโs lifetime risk of developing cancer by identifying specific genetic change. These gene variants may have harmful, beneficial, neutral, unknown, or uncertain effects in cancer risk. Up to 10 percent of all cancers may have a genetic cause. Hence, identification of these mutations in patient could help in improving patient care, including early detection, management, prognosis, risk reduction, use of targeted therapy and also understanding the implications for other family members.
The test results can help individuals and their healthcare providers understand their risk of developing cancer and make more informed decisions about preventive measures, such as increased screening or risk-reducing surgeries. The results can also inform the medical management of patients with a personal or family history of cancer.
๐ช๐ต๐ฎ๐ ๐ฎ๐ฟ๐ฒ ๐ต๐ฒ๐ฟ๐ฒ๐ฑ๐ถ๐๐ฎ๐ฟ๐ ๐ฐ๐ฎ๐ป๐ฐ๐ฒ๐ฟ๐?
Hereditary cancers are known to be genetic and the mutations are passed down in family members. People with positive variants in genes may present with hereditary cancer syndrome and are at a higher risk of getting certain cancers.
๐ช๐ต๐ฎ๐ ๐๐๐ฝ๐ฒ๐ ๐ผ๐ณ ๐ฐ๐ฎ๐ป๐ฐ๐ฒ๐ฟ๐ ๐ฎ๐ฟ๐ฒ ๐ฐ๐ผ๐บ๐บ๐ผ๐ป๐น๐ ๐ฎ๐๐๐ผ๐ฐ๐ถ๐ฎ๐๐ฒ๐ฑ ๐๐ถ๐๐ต ๐ต๐ฒ๐ฟ๐ฒ๐ฑ๐ถ๐๐ฎ๐ฟ๐ ๐ฐ๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐๐๐ป๐ฑ๐ฟ๐ผ๐บ๐ฒ๐?
Hereditary cancer syndromes can be associated with a variety of cancers, including breast, ovarian, colon, pancreatic cancer, melanoma, and others.
๐ช๐ต๐ฎ๐ ๐ถ๐ ๐๐ฒ๐ฟ๐ฒ๐ฑ๐ถ๐๐ฎ๐ฟ๐ ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐ฐ๐น๐ถ๐ป๐ถ๐ฐ?
Hereditary Cancer Clinic is a specialized medical facility that focuses on diagnosing and managing hereditary cancer syndromes. These clinics offer genetic counselling, testing, and personalized cancer risk assessments to individuals who have a family history of cancer or who may be at an increased risk of developing certain types of cancer.
๐๐ฒ๐ฟ๐ฒ๐ฑ๐ถ๐๐ฎ๐ฟ๐ ๐ฐ๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐ฐ๐น๐ถ๐ป๐ถ๐ฐ ๐ฎ๐ ๐๐ผ๐ธ๐ถ๐น๐ฎ๐ฏ๐ฒ๐ป
Hospital Mumbai focuses on personalized cancer care. Pre-test Genetic counselling is provided prior to testing and followed by post-test genetic consultations to help patients understand the test result and risks associated with it. A complete follow-up care to plan cancer prevention, timely surveillance and to provide individual personalized treatment strategies is arranged.
๐๐ฒ๐ฟ๐บ๐น๐ถ๐ป๐ฒ ๐ฐ๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐ฝ๐ฎ๐ป๐ฒ๐น ๐๐ฒ๐๐๐ถ๐ป๐ด ๐ฎ๐ ๐๐ผ๐ธ๐ถ๐น๐ฎ๐ฏ๐ฒ๐ป ๐๐ผ๐๐ฝ๐ถ๐๐ฎ๐น
Hereditary cancer is caused due to germline mutations /changes in genes that are passed from parents to offspring. Germline cancer panel testing typically includes the analysis of several cancer-related genes simultaneously, which may include genes such as BRCA1, BRCA2, TP53, and PTEN, among others. These genes are known to be associated with an increased risk of developing certain types of cancer, such as breast, ovarian, colon, prostate, lung, thyroid, bladder, hepatic cancers, melanoma, glioma, sarcomas and pancreatic cancer. The test results can help individuals and their healthcare providers understand their risk of developing cancer and therefore make more informed decisions about preventive measures, such as increased screening or risk-reducing surgeries.
Specialists at Kokilaben Hospital provide comprehensive genetic evaluations and testing based on 113 genes associated with cancers for patients whose family or personal history indicates they are at high risk of developing cancer. Kokilaben hospital is the only institute in the cancer offering such a broad panel of evaluation.
๐ฃ๐ฎ๐ป๐ฃ๐ฟ๐ฒ๐ฑ๐ถ๐ฐ๐ ๐๐๐ป๐ด ๐ฐ๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐ฃ๐ฎ๐ป๐ฒ๐น ๐ฎ๐ ๐๐ผ๐ธ๐ถ๐น๐ฎ๐ฏ๐ฒ๐ป ๐๐ผ๐๐ฝ๐ถ๐๐ฎ๐น
Kokilaben is the only Healthcare Institute in India to launch the PanPredict Lung cancer Panel on 11 predictive genes for both mutations and fusions (167 variants) mandatory for testing in advanced lung cancers. This test will be performed using Real time โ PCR which shows a very high sensitivity, specificity and turnaround time of only 5 days. This will be a game changer to help to improvise the treatment regime with an early effective strategy and patients will not have to wait for a month to start the treatment.
๐๐๐๐๐ฟ๐ฒ ๐ผ๐ณ ๐ฑ๐ถ๐ฎ๐ด๐ป๐ผ๐๐ถ๐
Kokilaben Hospital aims to make the centre of excellence of cancer as one of the biggest centre of genomic testing in India with personalized medicine and the treatments based on Cancer genomics. The hospital has invested into building up the population based genomic database of cancer patients to help understand the actionability of drugs.
Kokilaben Hospital has also subsidized the costs of genomic testing to make it more affordable. There are plans to invest and introduce in new technology to reduce the cost further.
